CDK4-pRB-E2F1 cell-cycle regulators are robustly expressed in non-proliferating β cells, suggesting that besides the control of β-cell number the CDK4-pRB-E2F1 pathway has a role in β-cell function. We show here that E2F1 directly regulates expression of Kir6.2, which is a key component of the K ATP channel involved in the regulation of glucose-induced insulin secretion. We demonstrate, through chromatin immunoprecipitation analysis from tissues, that Kir6.2 expression is regulated at the promoter level by the CDK4-pRB-E2F1 pathway. Consistently, inhibition of CDK4, or genetic inactivation of E2F1, results in decreased expression of Kir6.2, impaired insulin secretion and glucose intolerance in mice. Furthermore we show that rescue of Kir6.2 expression restores insulin secretion in E2f1 -/-β cells. Finally, we demonstrate that CDK4 is activated by glucose through the insulin pathway, ultimately resulting in E2F1 activation and, consequently, increased expression of Kir6.2. In summary we provide evidence that the CDK4-pRB-E2F1 regulatory pathway is involved in glucose homeostasis, defining a new link between cell proliferation and metabolism.
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CDK4-pRB-E2F1 cell-cycle regulators are robustly expressed in non-proliferating β cells, suggesting that besides the control of β-cell number the CDK4-pRB-E2F1 pathway has a role in β-cell function. We show here that E2F1 directly regulates expression of Kir6.2, which is a key component of the K ATP channel involved in the regulation of glucose-induced insulin secretion. We demonstrate, through chromatin immunoprecipitation analysis from tissues, that Kir6.2 expression is regulated at the promoter level by the CDK4-pRB-E2F1 pathway. Consistently, inhibition of CDK4, or genetic inactivation of E2F1, results in decreased expression of Kir6.2, impaired insulin secretion and glucose intolerance in mice. Furthermore we show that rescue of Kir6.2 expression restores insulin secretion in E2f1 -/-β cells. Finally, we demonstrate that CDK4 is activated by glucose through the insulin pathway, ultimately resulting in E2F1 activation and, consequently, increased expression of Kir6.2. In summary we provide evidence that the CDK4-pRB-E2F1 regulatory pathway is involved in glucose homeostasis, defining a new link between cell proliferation and metabolism.
E2F transcription factors exist either as free E2F/DP heterodimers, or associated in larger complexes containing members of the retinoblastoma (pRB, p107, p130), and of the cyc/cdk protein families. Association of E2Fs with the pRB family facilitates active repression through recruitment of histone deacetylases 1 and Lys/Arg methyl-transferases 2 . Subsequent phosphorylation of the retinoblastoma protein by the cyc/cdk complexes results in the release of the E2F transcription factors and activation of transcription of genes required for progression through G1 into the S phase of the cell cycle. It is now accepted that E2Fs participate in cellular processes beyond the cell cycle, including apoptosis, differentiation and development 3 . Of particular interest is the observation that E2Fs could be involved in the regulation of a metabolic network, including the control of mitochondrial function 4 .
Recently, we showed that E2Fs function in the control of adipocyte differentiation 5 . We also showed an overall reduction in pancreatic size, caused by impaired postnatal pancreatic growth in E2f 1 -/-mice 6 . Surprisingly, we observed that E2F1 was highly expressed in non-proliferating pancreatic β cells 6 , suggesting that besides its effect on β-cell number, E2F1 could also have a role in pancreatic β-cell function and insulin secretion. Pancreatic β-cell K ATP channels are formed by the heteromeric association of the sulfonylurea receptor 1 (SUR1) with the K + ATP channel inward rectifier (KIR6.2). These channels are essential in the regulation of glucose-induced insulin secretion by controlling membrane polarization 7, 8 . The first result suggesting a role of the CDK4-pRB-E2F1 pathway in pancreatic physiology, independently of cell proliferation, was the observation that E2F1, cyclin-dependent kinase-4 (CDK4) and pRB were expressed in almost all insulin-producing β cells (Fig. 1a) , whereas only a few of these cells (6%) were proliferating, as assessed by PCNA labelling ( Fig. 1b ; Supplementary Information, Fig. S1b ). Co-immunoprecipitation assays further indicated co-expression of pRB and E2F1 in these cells ( Supplementary  Information, Fig. S1a ). Participation of CDK4-pRB-E2F1 in glucose homeostasis was revealed by an intraperitoneal glucose tolerance test (IPGTT) showing that E2f -/-mice are glucose intolerant 6 (Fig. 1c) . Interestingly, insulin secretion in response to glucose was impaired in both E2f1 -/ -mice ( Fig. 1d ) and islets isolated from E2f1 -/-mice (Fig. 1e) . No difference in insulin content was observed in E2f1 -/-and E2f1 +/+ cells, when normalized to DNA content ( Supplementary Information, Fig. S1c ). This suggests that E2F1 is crucial for maintaining normal blood glucose levels through the control of insulin secretion in a cell-autonomous manner, instead of by affecting insulin synthesis. In contrast to E2f1 +/+ mice, E2f1 -/-mice are insensitive to glibenclamide, which is an antidiabetic drug of the sulfonylurea family that stimulates insulin secretion and therefore decreases blood glucose levels by blocking ATP-sensitive potassium channels in pancreatic β-cells. This finding suggests that E2F1 is involved in insulin secretion through the control of mechanisms such as plasma membrane depolarization (Fig. 1f) .
We next identified E2F1 target genes that could mediate the effects of E2F1 in β-cell biology. Comparative gene expression profiling revealed that several genes known to be involved in insulin production or secretion were differentially expressed between E2f1 -/-and E2f1 +/+ pancreatic islets ( Supplementary Information, Fig. S2a , Tables S1, S2) . Notably, mRNA expression of Kir6.2 (also referred as Kcnj11), which is a subunit of the inwardly rectifying and ATP-sensitive potassium channel, was markedly decreased in E2f1 -/-, compared with E2f1 +/+ islets, whereas expression of other genes involved in the control of insulin secretion, such as the sulfonylurea receptor Sur1, the pyruvate carboxylase (Pcx) or the uncoupling potein 2 (Ucp2), were not significantly changed (Fig. 2a) . Knockdown of E2F1 by a short interfering RNA (siRNA) decreased levels of endogenous Kir6.2 mRNA in isolated islets and in Min6 cells ( Fig. 2c, d ; Supplementary Information, Fig. S2c ) and resulted in decreased glucose-stimulated insulin secretion in Min6 cells ( Supplementary Information, Fig. S2d ). Most importantly, rescue of Kir6.2 expression in islets isolated from E2f 1 -/-mice restored glucosestimulated insulin secretion in these cells, demonstrating that Kir6.2 mediated the observed effects of E2F1 in insulin secretion ( Fig. 2e ; Supplementary Information, Fig. S2e ).
Computational analysis of the murine Kir6.2 promoter sequence revealed the presence of an E2F binding site located 577 base pairs upstream of the transcription start site ( Supplementary Information, Fig. S3a ). Transient transfection experiments indicated that the E2F1/DP-1 heterodimer could activate the Kir6.2 promoter up to 10-fold (Fig. 2f ). This transactivation capability was abrogated when the E2F1 response element found in the Kir6.2 promoter was mutated, suggesting that E2F1 was directly involved in the control of Kir6.2 promoter activity (Fig. 2f) . Binding of E2F1 on the promoter region of the Kir6.2 gene was demonstrated by chromatin immunoprecipitation (ChIP) experiments on genomic DNA isolated from whole pancreatic tissues. A fragment of the mouse Kir6.2 promoter containing the E2F binding site was amplified by PCR when different anti-E2F1 antibodies were used ( Fig. 2g; Supplementary Information,  Fig. S3b ). The same results were observed when chromatin isolated from islets was used (Fig. 2h) . No E2F1 was detected in an unrelated genomic region, or in pancreatic extracts from E2f 1 -/-mice, demonstrating the specificity of the binding ( Fig. 2g; Supplementary Information, Fig. S3c ). Electromobility shift assays showed that E2F1 bound directly to this site to the same extent as it binds to the consensus E2F1 binding site (Fig. S3d) . However, in the same assay, E2F1 could not bind to a mutated version of the E2F site in the Kir6.2 promoter ( Supplementary Information, Fig. S3d ). These results demonstrate that E2F1 regulates Kir6.2 expression through direct promoter binding in a cell-autonomous manner. The same results were obtained when Min6 cells were used ( Supplementary Information,  Fig. S3e ). In this cellular context, E2F1 was equally well associated with the Kir6.2 or Dhfr promoter, suggesting that the E2F1 response element found in the Kir6.2 promoter could be considered as a bona fide E2F1 target gene ( Supplementary Information, Fig. S3e ). E2F1 transcriptional activity is regulated through interactions with pocket proteins and cdks. When associated with pRB, E2Fs repress transcription. On phosphorylation of pRB by cdks, E2F1 is released and activates transcription of its target genes 9 . As E2F1 can regulate the expression of Kir6.2 (Fig. 2) , and Kir6.2 mRNA expression is regulated by glucose 10 , (Fig. 3a) we hypothesized that a glucose load could trigger the E2F1 pathway through inactivation of pRB by phosphorylation in pancreatic β cells. This was demonstrated by the observed increase in pancreatic CDK4 activity in response to glucose in mice, as measured by the capacity of immunoprecipitated CDK4 to phosphorylate recombinant pRB protein in vitro (Fig. 3b) . Consistent with this increase in CDK4 activity, enhanced pRB phosphorylation was observed in pancreatic islets in response to intraperitoneal glucose injection ( Fig. 3c; Supplementary Information,  Fig. S4 ). We also showed that glucose-induced phosphorylation of pRB increased E2F1 transcriptional activity towards the Kir6.2 promoter in reporter assays. Glucose treatment increased Kir6.2 promoter activity in the presence of the E2F1/DP-1 heterodimer, whereas no induction was observed when the E2F1 responsive element in the Kir6.2 promoter construct was mutated (Fig. 3d) . Moreover, co-transfection of increasing amounts of pRB counteracted the stimulatory effects of E2F1 on the Kir6.2 promoter (Fig. 3e) . Similarly, cell treatment with the CDK4 inhibitor IDCX (2-bromo-12,13-dihydro-5H-indolo(2,3-a)pyrrolo (3,4)carbazole), also repressed this E2F1-mediated transactivation of the Kir6.2 promoter activity (Fig. 3e) . These results were further validated by in vivo ChIP experiments. E2F1 was associated with the Kir6.2 promoter regardless of glucose treatment (Fig. 3f) . By contrast, pRB was only associated with this promoter region in the absence of glucose treatment, suggesting that glucose facilitated pRB release from the E2F1 complex bound to the Kir6.2 promoter (Fig. 3f) . This is consistent with the known repressor effect of hypophosphorylated pRB on E2F1 activity. To further prove that E2F1 and pRB are part of the same complex, re-ChIP experiments were performed. After a first ChIP using an anti-E2F1 antibody, a second immunoprecipitation using an anti-pRB antibody or non-specific IgGs was performed. The same results as in simple ChIP experiments were 
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Relative mRNA expression +/+ and E2f1 -/-isolated islets transfected with pCDNA3 or pCDNA3-mKir6.2 in the presence of 2.8 mM and 20 mM glucose. Results were normalized to total insulin and DNA content (mean ± s.e.m., n = 3). (f) The E2F1/DP-1 heterodimer modulates Kir6.2 promoter activity. COS7 cells were transiently co-transfected with the pGL3 (empty vector, negative control), the Kir6.2 promoter (Kir6.2-luc) and the mutated E2F1 responsive element Kir6.2 promoter (mutKir6.2-luc) luciferase constructs in the presence or absence of E2F1/DP-1. Results were normalized to β-galactosidase activity and are expressed as relative luciferase units (RLU). (g) ChIP demonstrating specific binding of E2F1 to the Kir6.2 promoter.
Crosslinked chromatin from E2f1
+/+ and E2f1 -/-pancreata was incubated with two different antibodies against E2F1 or IgG. Immunoprecipitates were analysed by PCR using specific primers for the E2F-RE present in the Kir6.2 promoter. As a control, a sample representing 10% of the total chromatin was included in the PCR (Input). observed, demonstrating that pRB forms a complex with E2F1 in this promoter under these conditions (Fig. 3g) . Finally, the physiological relevance of pRB phosphorylation was evaluated during glucose-stimulated insulin secretion. Transient transfection of a pRB non-phosphorylatable mutant (pRB
Δp34
, ref. 11) in Min6 cells resulted in a hypophosphorylated form of pRB under normal and glucose-stimulated conditions, whereas the wild-type form was still sensitive to phosphorylation (Fig. 3h) . Most importantly, expression of this mutant in Min6 cells resulted in decreased Kir6.2 mRNA expression ( Fig. 3i ) and subsequent glucosestimulated insulin secretion (Fig. 3j) . We can conclude from these results that phosphorylation of pRb is involved in glucose-stimulated insulin secretion through transcriptional control of Kir6.2 mRNA expression. Taken together these results suggest that glucose increases CDK4 activity, alleviates pRB-mediated repression and activates E2F1 transcriptional activity towards Kir6.2, highlighting a role for the CDK4-pRB-E2F1 pathway in the control of insulin function and glucose metabolism in pancreatic islets.
In pancreatic β cells, insulin regulates expression of genes such as the insulin gene itself 12 , or glucokinase 13 in response to glucose through autocrine effects. We therefore wanted to evaluate whether CDK4-pRB-E2F1 regulation of Kir6.2 expression by glucose was direct or mediated by autocrine effects of insulin. Concomitant treatment of glucose and diazoxide, a synthetic inhibitor of insulin secretion in β cells through opening of K + channels, abrogated the positive effect of glucose on Kir6.2 mRNA expression in these cells (Fig. 4a ). This transcriptional effect was mediated by E2F1, as shown by the absence of an effect in islets from E2f1 -/-mice (Fig. 4a) . Increased Kir6.2 expression in response to glucose correlated with increased CDK4 activity in pancreas of glucose-treated mice, as demonstrated by CDK4 kinase assays following immunoprecipitation of equal amounts of CDK4 (Fig. 4b) . Interestingly, blockade of insulin secretion with diazoxide, or inhibition of insulin signalling with LY290034, a phosphatidylinositol-3-kinase (PI(3)K) inhibitor, resulted in the abrogation of CDK4 activity in these mice (Fig. 4b) . The resulting decrease in CDK4 activity after diazoxide treatment correlated with increased binding of the repressor pRB-E2F1 complex on the Kir6.2 promoter, as demonstrated by in vivo ChIP and re-ChIP experiments (Fig. 4c, d ). This was consistent with the observed decrease in Kir6.2 mRNA expression. Similarly to diazoxide treatment, insulin secretion was inhibited in mice under fasting conditions. Consistently, the pRB-E2F1 repressor complex is associated with the Kir6.2 promoter. Conversely, glucose or insulin infusion in mice resulted in pRB phosphorylation (Fig. 4c, d ) and release from the E2F1 complex on the Kir6.2 promoter, leading to increased E2F1 transcriptional activity, as indicated by increased histone acetylation in the promoter region (Fig. 4c, d ). Taken together these results suggest that the effects of glucose on CDK4 activity, pRB phosphorylation and E2F1 transcriptional activity are mediated through an autocrine effect of insulin on β cells, which is secondary to glucose-stimulated insulin secretion.
We next investigated whether increased CDK4 activity after glucose and insulin treatment could be the result of increased regulatory activity of D-type cyclins, which are major regulators of CDK4. We observed a 2-to 3-fold increase in binding of cyclin D2 to CDK4 in Min6 cells treated with glucose, and most importantly with insulin, suggesting that insulin and glucose could exert their positive effects on CDK4 activity through an increase in cyclin D2 and CDK4 mRNA levels and subsequent protein-protein interaction (Fig. 4e, f) . The cell cycle is tightly regulated, with D-type cyclins acting as growth factor sensors. On mitogenic stimulation, D-type cyclin expression and assembly into CDK complexes is increased, resulting in cell-cycle progression. Interestingly, we observed that treatment of Min6 cells with the growth factors EGF or IGF resulted in increased mRNA levels of CcnD2 and Cdk4, and most importantly, increased Kir6.2 (Fig. 4g, h ). These data indicate that CDK4 activity is regulated by growth factor stimuli through increased mRNA levels of CcnD2 and CDK4, resulting in increased association of cyclin D2 and CDK4, which increases expression of Kir6.2 mRNA.
To unequivocally show that the CDK4-pRB-E2F1 pathway controls glucose homeostasis, we evaluated the effects of pharmacological inhibition of CDK4 activity on glucose tolerance and insulin secretion in mice. IDCX, a specific CDK4 inhibitor, caused a marked decrease in clearance of injected glucose, compared with untreated mice, as evaluated by IPGTT (Fig. 5a ). This was consistent with decreased glucose-stimulated insulin secretion in IDCX treated mice, compared with untreated mice (Fig. 5b) . In addition, inhibition of CDK4 activity in vivo resulted in decreased Kir6.2 mRNA and protein levels (Fig. 5c, d) . These results are of particular interest as they are similar to those observed in E2f 1 -/-mice and reinforce our hypothesis that the CDK4-pRB-E2F1 pathway has a crucial role in the control of glucose homeostasis.
We have previously demonstrated the importance of cell-cycle regulators, particularly E2Fs, in the control of postnatal pancreatic β-cell growth and replication. However, decreased proliferation and renewal rates of pancreatic β cells do not fully explain the observed decrease in insulin secretion in E2f1 -/-mice. We now provide enough evidence to propose that cell-cycle regulators, particularly the CDK4-pRB-E2F1 pathway, are essential mediators of nutrient sensing and insulin secretion. This is supported by several findings. First, E2F1, CDK4, and pRB proteins are highly expressed in β cells. However, only a few of these cells are proliferating, despite high expression levels of these cell-cycle regulators, suggesting an additional role of these proteins in β cells. Second, we show that E2F1 translates nutritional signalling, such as glucose, to a metabolic and not proliferative response through transcriptional regulation of specific β-cell genes involved in insulin secretion, such as Kir6. 2 -/-mice-both show impaired insulin secretion. Furthermore, these mice are not diabetic, despite impaired glucosestimulated insulin secretion, as insulin sensitivity in peripheral tissues is increased 5, 6, 14, 15 . These observations highlight a close link between E2F1 and KIR6.2 in metabolic function. Finally, we have demonstrated that the CDK4-pRB-E2F1 pathway is regulated through an autocrine effect of insulin on β cells, secondary to glucose-stimulated insulin secretion. We have shown here that β-cells respond to a high glucose concentration by inducing insulin secretion, which subsequently activates transcription by an autocrine effect ( Supplementary Information, Fig. S5 ). Transcriptional activation in β cells is controlled, at least in part, by insulin signalling through the PI(3)K/AKT pathway. We have shown that this pathway is implicated in CDK4-pRB-E2F1-mediated transcriptional regulation through increasing CDK4 kinase activity. CDK4, in turn, phosphorylates pRB and releases the E2F1-DP complex, which activates transcription of Kir6.2. Consistent with our hypothesis is the finding that CDK4 activity was increased in transgenic mice overexpressing a constitutively active form of AKT in β-cells (caAKT Tg ) 16 .
Participation of other cell-cycle regulators of the CDK4-pRB-E2F1 pathway in the metabolic response of pancreatic β-cells is likely. Similarly to E2f1
-/-mice, cyclin D1 -/-and cyclin D2 -/-mice show decreased β-cell mass concomitant with decreased insulin levels 17, 18 . Conversely, mice with gene inactivation of the cell-cycle inhibitors p27 (refs 19, 20) or p16 INK4A 21 have increased islet mass. These observations raise the question of how this cell-cycle regulatory pathway can regulate both cell proliferation and metabolism in β cells. Consistent with this duality is the established role of insulin as an important factor for both β-cell proliferation, and β-cell metabolic function [22] [23] [24] [25] . As our findings indicate that the CDK4-pRB-E2F1 pathway is regulated by insulin, we can hypothesize that both the proliferative and metabolic effects of insulin on β-cells are mediated by the increase in CDK4 activity and subsequent E2F1 transcriptional activity (Fig. 4) . Protein extracts, co-immunoprecipitation assays and immunoblot analysis. Protein extracts and sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE), electrotransfer and immunoblotting were performed as described previously 26 . Co-immunoprecipitation assays were performed as described previously 27 .
Immunofluorescence (IF) and immunohistochemistry (IHC).
IF and IHC were performed as described previously 6, 27 . Briefly, after antigen retrieval, 5-μm formalin-fixed pancreatic sections were incubated with the indicated antibodies (at 1:50 dilutions). Immunostainings were revealed using peroxidase-conjugated anti-rabbit (Jackson Immunoresearch) secondary antibodies and the DAB (for PCNA and phospho-Rb, DAKO) and NovaRed (for insulin, Vector Laboratories) chromogens as a substrate. Sections were counterstained with haematoxylin or methyl green. Immunofluorescence stainings were revealed using a FITCconjugated anti-rabbit (Jackson Immunoresearch), Alexa-conjugated anti-guinea pig, or anti-goat (for KIR6.2 staining, Jackson Immunoresearch) secondary antibody. Negative controls using rabbit or goat IgGs were performed and no staining was observed in these conditions.
Animal experiments. C57Bl/6J and E2f1
+/+ and E2f1 -/-mice were purchased from the Jackson Laboratory and were maintained according to European Union guidelines for use of laboratory animals. In vivo experiments were performed in compliance with the French guidelines for studies on experimental animal (Animal House agreement no. B-34-172-27, Authorization for Animal Experimentation no. 34.324). Glucose and insulin measurements were performed as described previously 6 on overnight-fasted mice immediately before and at the indicated time after intraperitoneal injections of glucose (2 g kg -1 ) and glibenclamide (5 mg kg -1 ). IDCX was injected intraperitoneally at a dose of 5 mg kg -1 day -1 for 3 days.
Pancreatic islet studies. Briefly, small pieces of pancreas were digested by collagenase (1.5 mg ml -1 ) and isolated in oxygenated Krebs-Ringer bicarbonate Hepes buffer (KRBH) containing 0.5% free fatty acid-free BSA. For insulin secretion assays, approximately five islets per condition were handpicked and exposed to either 2.8 or 20 mM glucose. Insulin released in the medium was measured 1 h later by radioimmunoassay (Linco Research). For Kir6.2 re-expression experiments, islets from E2f1 -/-mice were isolated as described above and cultured in DMEM medium supplemented with FBS and antibiotics in 12-well plates., Isolated islets were transfected 16 h later with empty pCDNA3 or pCDNA3 encoding the mKir6.2 cDNA (a gift from Y. Kurachi, Osaka University, Japan) using jetPEI (Polyplus Transfection) according to the manufacturer's instructions. Five hours after transfection, medium was replaced with fresh DMEM medium supplemented with FBS and antibiotics and islets were subsequently cultured for 20 h. For siRNA experiments, islets were transfected with DharmaFect2 (2 μl ml -1 ) and smart-pool E2F1 validated siRNA (100 nM) according to the manufacturer's instructions (Dharmacon) and cultured for 24 h in DMEM containing 2.8mM glucose and 10% FBS. Islets were then rinsed in PBS, handpicked (approximately five islets per condition, in triplicate) and pre-incubated in oxygenated-KRBH containing 0.5% FFA-free BSA for 30 min. After this pre-incubation step, islets transiently transfected with empty pCDNA3, pCDNA3-mKir6.2, control siRNA or E2F1 siRNA were incubated in oxygenated KRBH containing 2.8 or 20 mM glucose. Insulin released in the medium was measured using an insulin ELISA kit (Mercodia). Data are expressed as a ratio of DNA or total insulin content. For mRNA quantification, islets were isolated and incubated in KRBH containing 10 mM glucose for 1.5 h, then handpicked and finally incubated with or without 20 mM glucose, 100 nM insulin and/or inhibitors (200 μM diazoxide) for 1 h. Islets were then processed for mRNA extraction.
RNA extraction, Affymetrix arrays, RT-PCR and Q-PCR. After isolation of E2f1
+/+ and E2f1 -/-islets RNA extraction and reverse transcription were performed as described 6, 28 . mRNA expression was measured by quantitative real-time PCR (Q-PCR) with Power SYBR Green master mix using a 7300 ABI PRISM sequence detector system (Applied Biosystems) according to the manufacter's recommendations. Q-PCR was performed using gene-specific oligonu Chromatin immunoprecipitation (ChIP) and re-ChIP. ChIP and re-ChIP assays were performed as described previously 27 . Briefly, proteins from Min6 cells or pancreatic tissues were formaldehyde crosslinked to DNA. After homogeneization, lysis and DNA sonication, proteins were then immunoprecipitated using purified IgGs, anti-E2F1, anti-pRb or anti-acetyl H4 antibodies. After washing, for re-ChIP experiment, DNA-protein complexes were incubated in 10 mM dithiotreitol (DTT) at 37 °C for 30 min, diluted in re-ChIP buffer and subjected to a second immunoprecipitation. After washing, DNA-protein complexes obtained from ChIP and re-ChIP experiments were eluted and crosslinking was reversed by heating the samples at 65 °C for 16 h. DNA was then purified using Qiagen PCR purification kit and PCR amplification was performed using Kir6.2, FABP4 and Dhfr promoter-specific primers.
Electromobility shift assays. These assays were performed exactly as previously described using nuclear extracts from transfected Min6 cells with E2F1 and DP1 expression vectors 27 and radiolabelled gene-specific oligonucleotides (E2F-Dhfr, 5´-AATTCTGCGATTTCGCGCCAAACTTGACG-3´; E2F-Kir, 5´-TCAGGAGCCGATCTGGCGCCCTCTGGCGGC-3'; E2F-mutKir, 5´-TCAG-GAGCCGAGCGGCCGCCCGCCGGCGGC-3´).
Kinase assays. Mice were fasted for 16 h, injected intraperitoneally with glucose (2 g kg -1 ) and glucose (2 g kg -1 ) combined with diazoxide (25 mg kg -1 ) or LY290034 (100 mg kg -1 ). Mice were then killed and CDK4 immunoprecipitation and kinase assays were performed exactly as described previously 29 . Briefly, kinase assays were performed using immunoprecipitated CDK4 and 100 ng of recombinant Rb protein (Santa Cruz) as a substrate. Reactions were performed in kinase buffer (25 mM Tris/HCl [pH 7.5], 150 mM NaCl, 10 mM MgCl2, 1 mM DTT, 5 mM Na4P2O7, 50 mM NaF, 1 mM vanadate and protease inhibitor cocktail (Sigma)) using 40 μM ATP and 8 μCi γ-33 P-ATP for 30 min at 37 °C. CDK6/cycD3 kinase (Upstate) was used as positive nature cell biology control. The reaction was stopped by boiling the samples for 5 min in the presence of denaturing sample buffer. Samples were subsequently subjected to SDS-PAGE, and the gels were then dried in a gel dryer for 1 h at 80°C and exposed to an X-ray film.
Statistical analysis. Data are presented as mean ± s.e.m.; statistical analyses was performed using unpaired Student's t-test. Differences were considered statistically significant at P <0.05. (*P <0.05; ** P <0.01 and *** P <0.001). E2F1/DP-1
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Figure S5
Model of regulation of the CDK4-pRB-E2F1 pathway in the pancreas. In pancreas the CDK4-pRB-E2F1 pathway exerts both proliferative and metabolic functions, such as the control of both pancreatic growth and insulin secretion, respectively. Under low glucose condition, such as observed during fasting, the Kir6.2 gene is repressed in β-cell due to the concomitant binding of E2F1, DP-1 and pRb.
In response to increased glucose levels, insulin is secreted and acts through an autocrine effect on β-cells, activating the PI3 kinase, which consequently increases CDK4 activity, phosphorylation of pRB and subsequent E2F1 transcriptional activity. In this condition, high glucose concentration will activate transcription of E2F1 target gene, i.e. the Kir6.2 gene. 
